Search
Explore our resource library to learn more about the B·R·A·H·M·S MR-proADM Assay
Videos
Integration of B·R·A·H·M·S MR-proADM KRYPTOR into clinical risk assessment may support clinical decision making in the ED on level of care
MR-proADM has been shown to identify the likelihood of furtherdisease progression in patients presenting to the ED with asuspected infection. Saeed K. et al. Crit Care, 2019 Feb8:23(1)40
Thermo Scientific B·R·A·H·M·S MR-proADM can help to manage overcrowded Emergency Departments by supporting discharge decisions.
The use of MR-proADM in the emergency department can help with the assessment risk of further disease progression and thereby may support outpatient treatment decisions.
Helpful documents
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S MR-proADM is a registered trademark of B·R·A·H·M·S GmbH.
Nobel Prize is a registered trademark of the Nobel Foundation. Other product names in this document are used for identification purposes; they may be trademarks and/or registered trademarks of their respective companies.
TRACE and KRYPTOR are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific.
View patents and patent marking.